Joel Greenblatt’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.9M | Sell |
102,500
-5,544
| -5% | -$369K | 0.02% | 878 |
|
|
2026
Q1 | $6.79M | Buy |
108,044
+25,791
| +31% | +$1.8M | 0.02% | 792 |
|
|
2025
Q4 | $5.46M | Buy |
82,253
+68,699
| +507% | +$4.44M | 0.02% | 793 |
|
|
2025
Q3 | $912K | Sell |
13,554
-69,798
| -84% | -$5.52M | ﹤0.01% | 1229 |
|
|
2025
Q2 | $7.28M | Sell |
83,352
-30,210
| -27% | -$2.37M | 0.04% | 553 |
|
|
2025
Q1 | $7.76M | Sell |
113,562
-1,120
| -1% | -$91.4K | 0.06% | 415 |
|
|
2024
Q4 | $8.92M | Buy |
114,682
+35,883
| +46% | +$2.66M | 0.08% | 337 |
|
|
2024
Q3 | $5.28M | Buy |
78,799
+30,919
| +65% | +$2.54M | 0.05% | 473 |
|
|
2024
Q2 | $5.43M | Buy |
47,880
+8,276
| +21% | +$1.05M | 0.07% | 404 |
|
|
2024
Q1 | $5.49M | Sell |
39,604
-168
| -0.4% | -$21.1K | 0.08% | 327 |
|
|
2023
Q4 | $4.94M | Sell |
39,772
-40,027
| -50% | -$4.09M | 0.09% | 302 |
|
|
2023
Q3 | $7.45M | Buy |
79,799
+46,879
| +142% | +$5.28M | 0.15% | 133 |
|
|
2023
Q2 | $4.23M | Sell |
32,920
-12,090
| -27% | -$1.46M | 0.09% | 292 |
|
|
2023
Q1 | $5.23M | Sell |
45,010
-48,296
| -52% | -$5.41M | 0.13% | 182 |
|
|
2022
Q4 | $10.6M | Buy |
93,306
+55,181
| +145% | +$6.06M | 0.3% | 48 |
|
|
2022
Q3 | $3.07M | Buy |
38,125
+18,855
| +98% | +$1.6M | 0.09% | 263 |
|
|
2022
Q2 | $1.44M | Sell |
19,270
-10,286
| -35% | -$939K | 0.05% | 456 |
|
|
2022
Q1 | $3.78M | Buy |
29,556
+10,804
| +58% | +$1.18M | 0.12% | 214 |
|
|
2021
Q4 | $2.52M | Buy |
18,752
+15,904
| +558% | +$2.29M | 0.08% | 298 |
|
|
2021
Q3 | $389K | Buy |
+2,848
| New | +$359K | 0.02% | 739 |
|
|
2021
Q1 | – | Sell |
-6,944
| Closed | -$642K | – | 1010 |
|
|
2020
Q4 | $642K | Sell |
6,944
-3,940
| -36% | -$352K | 0.02% | 655 |
|
|
2020
Q3 | $1.12M | Buy |
10,884
+3,944
| +57% | +$412K | 0.04% | 509 |
|
|
2020
Q2 | $703K | Sell |
6,940
-100,308
| -94% | -$8.97M | 0.02% | 663 |
|
|
2020
Q1 | $7.22M | Buy |
107,248
+90,800
| +552% | +$5.65M | 0.2% | 147 |
|
|
2019
Q4 | $899K | Buy |
+16,448
| New | +$780K | 0.02% | 649 |
|
|
2018
Q2 | – | Sell |
-40,160
| Closed | -$745K | – | 912 |
|
|
2018
Q1 | $745K | Buy |
+40,160
| New | +$594K | 0.01% | 658 |
|
|
2015
Q1 | – | Sell |
-39,660
| Closed | -$546K | – | 932 |
|
|
2014
Q4 | $546K | Buy |
+39,660
| New | +$486K | ﹤0.01% | 720 |
|
|
2014
Q3 | – | Sell |
-32,132
| Closed | -$319K | – | 1005 |
|
|
2014
Q2 | $319K | Buy |
+32,132
| New | +$285K | ﹤0.01% | 871 |
|
Other funds holding DXCM
Joel Greenblatt's DXCM Position: Q2 2026 in Review
Joel Greenblatt reduced its DexCom (DXCM) stake by 5.1% in Q2 2026, selling an estimated $369K and leaving 102,500 shares worth $6.9M. The position accounts for 0.02% of the portfolio, ranked #878.
Joel Greenblatt first reported a position in DXCM in Q2 2014 and has held it in 28 quarters since. The position peaked at $10.6M in Q4 2022. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Joel Greenblatt held 102,500 shares of DexCom worth $6.9M as of Q2 2026.
- Joel Greenblatt sold 5,544 DexCom shares in Q2 2026, an estimated $369K.
- DexCom made up 0.02% of Joel Greenblatt's portfolio in Q2 2026, its #878 holding.
- Joel Greenblatt first reported a position in DexCom in Q2 2014 and has held it in 28 quarters since.
- Joel Greenblatt's DexCom position peaked at $10.6M in Q4 2022.
- 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.